phentermine has been researched along with Cardiovascular Diseases in 20 studies
Phentermine: A central nervous system stimulant and sympathomimetic with actions and uses similar to those of DEXTROAMPHETAMINE. It has been used most frequently in the treatment of obesity.
Cardiovascular Diseases: Pathological conditions involving the CARDIOVASCULAR SYSTEM including the HEART; the BLOOD VESSELS; or the PERICARDIUM.
| Excerpt | Relevance | Reference |
|---|---|---|
| " Controlled-release phentermine/topiramate (PHEN/TPM CR), as an adjunct to lifestyle modification, has previously shown significant weight loss compared with placebo in a 56-wk study in overweight and obese subjects with ≥2 weight-related comorbidities." | 9.16 | Two-year sustained weight loss and metabolic benefits with controlled-release phentermine/topiramate in obese and overweight adults (SEQUEL): a randomized, placebo-controlled, phase 3 extension study. ( Allison, DB; Bowden, CH; Day, WW; Gadde, KM; Garvey, WT; Look, M; Peterson, CA; Ryan, DH; Schwiers, M, 2012) |
| " Cardiovascular data associated with long-term use of phentermine and topiramate extended-release indicate that this combination may be a safe and effective option for reducing weight in overweight/obese patients at low-to-intermediate cardiovascular risk." | 6.50 | Cardiovascular effects of phentermine and topiramate: a new drug combination for the treatment of obesity. ( Astrup, A; Day, WW; Engeli, S; Finer, N; Jordan, J; Narkiewicz, K, 2014) |
| "Qsymia is a combination of phentermine and topiramate used for obesity treatment." | 6.49 | Phentermine and topiramate extended-release for the obesity: new kids on the block. ( Kallikazaros, I; Kallistratos, MS; Katsi, V; Makris, T; Manolis, AJ; Marketou, M; Tousoulis, D; Vardas, P, 2013) |
| " Controlled-release phentermine/topiramate (PHEN/TPM CR), as an adjunct to lifestyle modification, has previously shown significant weight loss compared with placebo in a 56-wk study in overweight and obese subjects with ≥2 weight-related comorbidities." | 5.16 | Two-year sustained weight loss and metabolic benefits with controlled-release phentermine/topiramate in obese and overweight adults (SEQUEL): a randomized, placebo-controlled, phase 3 extension study. ( Allison, DB; Bowden, CH; Day, WW; Gadde, KM; Garvey, WT; Look, M; Peterson, CA; Ryan, DH; Schwiers, M, 2012) |
| "In the population of patients with obesity and CVD, the medications orlistat, lorcaserin and liraglutide are considered the most appropriate options for their treatment, in terms of safety." | 5.01 | Treating obesity in patients with cardiovascular disease: the pharmacotherapeutic options. ( Andrew, CA; Aronne, LJ; Saunders, KH; Shukla, AP, 2019) |
| " Food and Drug Administration has approved three weight loss agents: sibutramine, orlistat, and phentermine." | 4.83 | Use of lifestyle changes treatment plans and drug therapy in controlling cardiovascular and metabolic risk factors. ( Pi-Sunyer, FX, 2006) |
| " We performed disproportionality analyses to detect cardiovascular safety signals with three antiobesity drugs recently approved for marketing: lorcaserin, naltrexone-bupropion, phentermine, and phentermine-topiramate." | 3.96 | The cardiovascular safety of antiobesity drugs-analysis of signals in the FDA Adverse Event Report System Database. ( Gorelik, B; Gorelik, E; Hirsh-Raccah, B; Masarwa, R; Matok, I; Perlman, A, 2020) |
| "The aim of this work was to study weight loss and risk of cardiovascular disease (CVD) or death associated with longer-term phentermine use." | 3.91 | Safety and Effectiveness of Longer-Term Phentermine Use: Clinical Outcomes from an Electronic Health Record Cohort. ( Ard, J; Arterburn, DE; Barton, L; Bessesen, DH; Daley, MF; Desai, J; Fischer, H; Fitzpatrick, SL; Horberg, M; Koebnick, C; Lewis, KH; Oshiro, C; Yamamoto, A; Young, DR, 2019) |
| "To evaluate, in compliant patients, the pharmaceutical costs of treating obesity with fenfluramine/mazindol, fenfluramine/phentermine, caffeine/ephedrine, or mazindol relative to the pharmaceutical costs of treating obesity-related comorbid conditions and reducing cardiovascular risk." | 3.70 | Pharmaceutical cost savings of treating obesity with weight loss medications. ( Bray, GA; Greenway, FL; Rood, JC; Ryan, DH; Smith, SR; Tucker, EW, 1999) |
| " Cardiovascular data associated with long-term use of phentermine and topiramate extended-release indicate that this combination may be a safe and effective option for reducing weight in overweight/obese patients at low-to-intermediate cardiovascular risk." | 2.50 | Cardiovascular effects of phentermine and topiramate: a new drug combination for the treatment of obesity. ( Astrup, A; Day, WW; Engeli, S; Finer, N; Jordan, J; Narkiewicz, K, 2014) |
| "Obesity is a major correlate of cardiovascular disease." | 2.50 | Modern obesity pharmacotherapy: weighing cardiovascular risk and benefit. ( Cunningham, JW; Wiviott, SD, 2014) |
| "Qsymia is a combination of phentermine and topiramate used for obesity treatment." | 2.49 | Phentermine and topiramate extended-release for the obesity: new kids on the block. ( Kallikazaros, I; Kallistratos, MS; Katsi, V; Makris, T; Manolis, AJ; Marketou, M; Tousoulis, D; Vardas, P, 2013) |
| " Receptorome screening has implicated N-deethylation of fenfluramine and serotonin 5-hydroxy-t-ryptamine 2B receptors in the adverse effects of the drug; subsequent studies corroborated this finding." | 2.43 | Screening the receptorome reveals molecular targets responsible for drug-induced side effects: focus on 'fen-phen'. ( Roth, BL; Setola, V, 2005) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 2 (10.00) | 18.2507 |
| 2000's | 4 (20.00) | 29.6817 |
| 2010's | 13 (65.00) | 24.3611 |
| 2020's | 1 (5.00) | 2.80 |
| Authors | Studies |
|---|---|
| Gorelik, E | 1 |
| Gorelik, B | 1 |
| Masarwa, R | 1 |
| Perlman, A | 1 |
| Hirsh-Raccah, B | 1 |
| Matok, I | 1 |
| Andrew, CA | 1 |
| Saunders, KH | 1 |
| Shukla, AP | 1 |
| Aronne, LJ | 1 |
| Lewis, KH | 1 |
| Fischer, H | 1 |
| Ard, J | 1 |
| Barton, L | 1 |
| Bessesen, DH | 1 |
| Daley, MF | 1 |
| Desai, J | 1 |
| Fitzpatrick, SL | 1 |
| Horberg, M | 1 |
| Koebnick, C | 1 |
| Oshiro, C | 1 |
| Yamamoto, A | 1 |
| Young, DR | 1 |
| Arterburn, DE | 1 |
| Katsi, V | 1 |
| Marketou, M | 1 |
| Kallistratos, MS | 1 |
| Tousoulis, D | 2 |
| Makris, T | 1 |
| Manolis, AJ | 1 |
| Vardas, P | 1 |
| Kallikazaros, I | 1 |
| Charakida, M | 1 |
| Finer, N | 2 |
| Jordan, J | 1 |
| Astrup, A | 1 |
| Engeli, S | 1 |
| Narkiewicz, K | 1 |
| Day, WW | 3 |
| Cunningham, JW | 1 |
| Wiviott, SD | 1 |
| Alfaris, N | 1 |
| Minnick, AM | 1 |
| Hopkins, CM | 1 |
| Berkowitz, RI | 1 |
| Wadden, TA | 1 |
| Rothman, RB | 1 |
| Hendricks, EJ | 2 |
| Wilbert, B | 1 |
| Mohundro, BL | 1 |
| Shaw, V | 1 |
| Andres, A | 1 |
| Garvey, WT | 1 |
| Ryan, DH | 2 |
| Look, M | 1 |
| Gadde, KM | 1 |
| Allison, DB | 1 |
| Peterson, CA | 1 |
| Schwiers, M | 2 |
| Bowden, CH | 2 |
| Apovian, CM | 1 |
| Gokce, N | 1 |
| Davidson, MH | 1 |
| Tonstad, S | 1 |
| Oparil, S | 1 |
| Setola, V | 1 |
| Roth, BL | 1 |
| Pi-Sunyer, FX | 1 |
| Greenway, FL | 1 |
| Bray, GA | 1 |
| Rood, JC | 1 |
| Tucker, EW | 1 |
| Smith, SR | 1 |
| Curzon, G | 1 |
| Gibson, EL | 1 |
| Kilpatrick, IC | 1 |
| Traut, M | 1 |
| Heal, DJ | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Medications After Adolescent Bariatric Surgery Protocol for Inadequate Weight Loss Following Sleeve Gastrectomy in Adolescents and Young Adults: A Pilot Feasibility Study[NCT04572217] | Phase 2 | 0 participants (Actual) | Interventional | 2022-06-30 | Withdrawn (stopped due to No available funding) | ||
| A Phase 3, Double-Blind, Placebo-Controlled, Multicenter Extension Study (From Study OB-303 [NCT00553787]) to Determine the Safety and Efficacy Of VI-0521 for the Long-Term Treatment Of Obesity in Adults With Obesity-Related Co-Morbid Conditions.[NCT00796367] | Phase 3 | 676 participants (Actual) | Interventional | 2008-12-31 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
(NCT00796367)
Timeframe: From baseline to end of treatment
| Intervention | percent weight loss (Least Squares Mean) |
|---|---|
| Placebo | -1.8 |
| VI-0521 Mid | -9.32 |
| VI-0521 Top | -10.5 |
(NCT00796367)
Timeframe: Baseline to End of Treatment
| Intervention | percent participants (Number) |
|---|---|
| Placebo | 30 |
| VI-0521 Mid | 75.2 |
| VI-0521 Top | 79.3 |
9 reviews available for phentermine and Cardiovascular Diseases
| Article | Year |
|---|---|
Treating obesity in patients with cardiovascular disease: the pharmacotherapeutic options.
Topics: Anti-Obesity Agents; Benzazepines; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Humans; Lirag | 2019 |
Phentermine and topiramate extended-release for the obesity: new kids on the block.
Topics: Animals; Anti-Obesity Agents; Cardiovascular Diseases; Delayed-Action Preparations; Drug Combination | 2013 |
Drug treatment of obesity in the cardiovascular patient.
Topics: Anti-Obesity Agents; Benzazepines; Cardiovascular Diseases; Fructose; Humans; Lactones; Obesity; Orl | 2013 |
Cardiovascular effects of phentermine and topiramate: a new drug combination for the treatment of obesity.
Topics: Aged; Anti-Obesity Agents; Appetite Depressants; Cardiovascular Diseases; Clinical Trials, Phase III | 2014 |
Modern obesity pharmacotherapy: weighing cardiovascular risk and benefit.
Topics: Anti-Obesity Agents; Benzazepines; Bupropion; Cardiovascular Diseases; Clinical Trials as Topic; Dru | 2014 |
Combination phentermine and topiramate extended release in the management of obesity.
Topics: Anti-Obesity Agents; Cardiovascular Diseases; Clinical Trials, Phase II as Topic; Clinical Trials, P | 2015 |
Screening the receptorome reveals molecular targets responsible for drug-induced side effects: focus on 'fen-phen'.
Topics: Animals; Appetite Depressants; Cardiovascular Diseases; Drug Evaluation, Preclinical; Drug-Related S | 2005 |
Use of lifestyle changes treatment plans and drug therapy in controlling cardiovascular and metabolic risk factors.
Topics: Caloric Restriction; Cardiovascular Diseases; Cyclobutanes; Diabetes Mellitus; Diet; Diet, Fat-Restr | 2006 |
The serotonergic appetite suppressant fenfluramine. Reappraisal and rejection.
Topics: Appetite; Brain; Cardiovascular Diseases; Fenfluramine; Humans; Phentermine; Selective Serotonin Reu | 1999 |
1 trial available for phentermine and Cardiovascular Diseases
| Article | Year |
|---|---|
Two-year sustained weight loss and metabolic benefits with controlled-release phentermine/topiramate in obese and overweight adults (SEQUEL): a randomized, placebo-controlled, phase 3 extension study.
Topics: Adult; Anti-Obesity Agents; Cardiovascular Diseases; Delayed-Action Preparations; Diabetes Mellitus; | 2012 |
10 other studies available for phentermine and Cardiovascular Diseases
| Article | Year |
|---|---|
The cardiovascular safety of antiobesity drugs-analysis of signals in the FDA Adverse Event Report System Database.
Topics: Adult; Adverse Drug Reaction Reporting Systems; Aged; Anti-Obesity Agents; Benzazepines; Cardiovascu | 2020 |
Safety and Effectiveness of Longer-Term Phentermine Use: Clinical Outcomes from an Electronic Health Record Cohort.
Topics: Adolescent; Adult; Anti-Obesity Agents; Cardiovascular Diseases; Cause of Death; Cohort Studies; Ele | 2019 |
Phentermine cardiovascular safety. In response to Yosefy C, Berman M, Beeri R. Cusp tear in bicuspid aortic valve possibly caused by phentermine. International journal of cardiology 2006;106:262-3.
Topics: Aortic Valve; Appetite Depressants; Cardiovascular Diseases; Heart Valve Diseases; Humans; Obesity; | 2010 |
Appetite suppressants as adjuncts for weight loss.
Topics: Appetite Depressants; Cardiovascular Diseases; Chemotherapy, Adjuvant; Diethylpropion; Evidence-Base | 2011 |
Obesity and cardiovascular disease.
Topics: Adult; Anti-Obesity Agents; Atrial Fibrillation; Bariatric Surgery; Cardiovascular Diseases; Diabete | 2012 |
Letter by hendricks regarding article, "obesity and cardiovascular disease".
Topics: Anti-Obesity Agents; Atrial Fibrillation; Bariatric Surgery; Cardiovascular Diseases; Humans; Male; | 2012 |
Changes in cardiovascular risk associated with phentermine and topiramate extended-release in participants with comorbidities and a body mass index ≥27 kg/m(2).
Topics: Anti-Obesity Agents; Biomarkers; Body Mass Index; Cardiovascular Diseases; Comorbidity; Delayed-Acti | 2013 |
Contingent fees in mass tort litigation.
Topics: Appetite Depressants; Cardiovascular Diseases; Compensation and Redress; Fees and Charges; Fenfluram | 2006 |
Pharmaceutical cost savings of treating obesity with weight loss medications.
Topics: Adolescent; Adult; Appetite Depressants; Caffeine; Cardiovascular Diseases; Diabetes Mellitus; Drug | 1999 |
Monoamine oxidase inhibition is unlikely to be relevant to the risks associated with phentermine and fenfluramine: a comparison with their abilities to evoke monoamine release.
Topics: Animals; Brain; Cardiovascular Diseases; Fenfluramine; Male; Monoamine Oxidase; Monoamine Oxidase In | 2001 |